Introduction
Haemostasis occurs in a physiological setting to seal a breach in the vasculature and preserve its integrity.
Thrombosis, on the other hand, is coagulation in a pathological setting that may lead to inappropriate occlusion of a vessel [1] . Human physiology requires five components to seamlessly interact at the appropriate times to achieve haemostasis and avoid thrombosis. These components are: platelets; coagulation factors; coagulation inhibitors; fibrinolysis; and blood vessels. There is a fine balance between the procoagulant and anticoagulant elements.
The surgical insult, no matter how trivial, causes bleeding, even a small amount of which can be catastrophic in closed compartments during ophthalmic and spinal operations or neurosurgery. The crucial questions are how brisk and how controllable will the bleeding be, particularly when patients have surgery for the first time.
The historical routine testing of coagulation before scheduled surgery has been displaced by selected testing of coagulation, as summarised by the 2008 British Committee for Standards in Haematology and a subsequent editorial [2] [3] [4] [5] [6] [7] [8] . Selected testing costs less, reduces waste and delay and increases negative and positive predictive values [9] .
The National Institute for Health and Care Excellence (NICE) has incorporated selective testing in its guideline, 'Routine pre-operative tests for elective surgery', which recommends tests of haemostasis only for patients with a history of abnormal bleeding, anticoagulant medication or liver disease, those who are ASA physical status 3 or 4, and before intermediate or major surgery [10] . The prothrombin time (PT) is the most commonly used coagulation test, in part due to the prevalence of coumarin anticoagulants, such as warfarin. However, the activated partial thromboplastin time (APTT) is informative, abnormalities of which can signal significant underlying haemostatic dysfunction.
Modelling the coagulation cascade
The PT and APTT assess the initiation and propagation of haemostasis, respectively, traditionally modelled as 'extrinsic' and 'intrinsic' pathways, which join to form the 'common pathway' (Fig. 1 ). This useful in-vitro model is a simplification of events in vivo. It explains the most common coagulation assays in a practical way and guides further investigation. We will therefore use this model throughout this article, despite its limitations. The PT tests the function of the extrinsic pathway, which is dependent on clotting factor VII. The APTT tests the function of the intrinsic pathway, which is dependent on factors VIII, IX, XI and XII.
Coagulation factors X, V, II and fibrinogen are the common pathway and are tested by both the PT and the APTT. Figure 1 The traditional model of the coagulation cascade, adapted from Price et al. [44] . The intrinsic pathway is coloured green, the extrinsic coloured red and the common pathway is blue. *denotes factors that are commonly deficient when an isolated prolonged APTT is found (although it is rare to perform a factor XII assay). † denotes factors that most commonly develop direct inhibitors in vivo.
The coagulation screen
time (PT) is tested by mixing platelet-poor plasma with tissue factor (previously known as tissue thromboplastin) and phospholipid, at 37°C: the time taken for a fibrin clot to form after adding calcium is the prothrombin time (PT), detected by increased optical density [11] .
The word 'partial' in 'activated partial thromboplastin time' refers to the activation of clotting by phospholipid, not tissue factor. A prolonged APTT suggests deficiency of coagulation factors II, V, VIII, IX, X, XI, XII or fibrinogen.
The APTT is tested by mixing platelet-poor plasma with phospholipid and a contact activator, such as kaolin or micronised silica, at 37°C: the time taken for a fibrin clot to form after adding calcium is the APTT. The lupus anticoagulant -a misnomer as it is procoagulant -is an antibody that binds phospholipids and prolongs most APTT assays, but a few assays use reagents that are not bound. The binding capacity of the lupus anticoagulant is exceeded by the high concentration of phospholipid used for the PT test, which is usually not prolonged except at very high antibody titres [13] . Coagulation factors may also be bound by acquired autoantibodies or alloantibodies (from repeated infusions), the commonest of which antagonises factor VIII (acquired haemophilia A). Coagulation factor antibodies may develop with multiple myeloma, Waldenstrom's macroglobulinaemia and rarely other lymphoid malignancies [14] . Routine coagulation assays are variably affected by direct oral anticoagulants (DOACs), the effects of which are determined by specialist assays such as an anti-factor Xa-based assay [15] . The APTT and PT are affected unpredictably by direct thrombin inhibitors, such as bivalirudin and argatroban, the effects of which would be best tested by the ecarin clotting time (a measure of hirudin activity), but this is rarely available in practice. We found 64 articles, 16 of which we identified as potentially relevant [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . We subsequently decided six of these were inappropriate for our purpose: one was specific to Singapore [17] ; three were insufficiently detailed [18] [19] [20] and two only discussed monitoring unfractionated heparin [21, 22] . Of the remaining 10 articles, four discussed acquired coagulation disorders [23] [24] [25] [26] and six discussed direct oral anticoagulants [27] [28] [29] [30] [31] [32] . Three reviews agreed a diagnostic algorithm for isolated prolonged APTT: exclusion of a spurious result, for instance due to sample contamination; a 1:1 mixing study; appropriate factor assays; lupus anticoagulant assessments; and anti-factor antibody enzyme assays [23] [24] [25] . Five reviews accepted that APTT can detect effects of directly acting oral anticoagulants (DOAC), but the APTT cannot reliably quantify the effect as reagents vary in their sensitivity to these drugs, with dose-response relationships that may be non-linear [27] [28] [29] [30] [31] . The correlation between DOAC dose and APTT is most reliable for dabigatran, with a dose-response slope that is linear at doses of 200-300 ng.ml
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, with a plateau at higher doses [27, 28, [30] [31] [32] . One review discussed a two-test APTT calculator for dabigatran dose [30] . Nevertheless, the recommendation is that APTT should not be used to measure DOAC effect, and instead drug-specific assays should be used [33] .
Deranged pre-operative APTT
Unselected coagulation tests cause unnecessary patient concern, they may delay surgery unnecessarily and results may be misinterpreted, due to the failure to recognise the limitations of laboratory results (normal and abnormal) in describing in vivo phenomena [7] . A comprehensive bleeding history is crucial, it should detail: previous trauma and surgery; pregnancy and related procedures; bleeding and thrombosis in consan- 
Lupus anticoagulant
The 'lupus anticoagulant (LA)' is a heterogenous group of immunoglobulins (mainly IgG and sometimes IgM) that bind a range of plasma proteins attached to anionic phospholipids. They are prothrombotic -'anticoagulant' is a misnomer, consequent on their prolongation of the APTT. Their procoagulant effect is poorly understood: it involves alterations in the degradation of protein C and protein S [35] . The autoantibodies are not only found in 5-34% of patients with systemic lupus erythematosus but also other general medical pathologies [35, 36] . Most notably, one study postulated a link between sepsis, catecholamine use and the development of lupus anticoagulant, which has implications for anaesthesia in the critically ill [37] . In most cases, lupus anticoagulant is transient and resolves within weeks of its identification [38] . Lupus anticoagulant that is associated with acute thrombosis and that persists for more than 12 weeks suggests primary antiphospholipid syndrome (APS), which may increase the probability of postoperative thrombosis and indicates extended postoperative thromboprophylaxis, whereas transient lupus anticoagulant that is not associated with thrombosis should not change peri-operative care [38, 39] . 
Abnormal APTT before elective surgery
It is difficult to give a value above which an isolated prolonged APTT should cause concern to the anaesthetist. A 'normal' APTT can be returned when there is a factor deficiency of up to 20-30% [2] . Current practice in haematology is moving towards the use of absolute times, with APTT ratio relegated to monitoring the effect of heparin infusion. The absolute APTT and its index, test time/control time, are dependent on local laboratory reagents and test conditions [40] . Reviews have variously recommended the investigation of an APTT index > 1.5 or 1.8, perhaps with a lower threshold for transfusion of blood products in trauma, a circumstance in which the PT is more sensitive for detecting coagulation factor deficiency [41] [42] [43] . Conversely, one review recommended that any prolonged APTT should be investigated, to exclude acquired haemophilia A [26] . We recommend that an APTT that exceeds the upper limit of the laboratory's normal range should be investigated, rather than a time > 40 s.
A patient should be considered as at high risk of bleeding if they have an abnormal bleeding history combined with prolonged APTT, particularly if the index exceeds 1.8 [41, 42] . Derangements of platelet number or function, or the presence of prolonged PT, should lower the threshold at which a prolonged APTT should be investigated, particularly with acute trauma [43] .
We recommend the following algorithm for an isolated prolonged APTT ( 4 If no heparin is detected, the next step is 'mixing studies' [23] [24] [25] . The mixing study relies on the principle that if the APTT is repeated after the patient's plasma is mixed with normal plasma in a 1:1 ratio, then the APTT should normalise (as 50% normal clotting factors are available). This suggests that the initial sample was deficient in one or more coagulation factors.
5 If this is the case, the next step is to perform specific factor assays to identify which factor or factors are responsible [23] [24] [25] [26] . This will be one of the factors of the intrinsic pathway; factors VIII, IX, XI or XII. Often, laboratories will not perform a factor XII or contact factor assays as deficiency of these do not lead to a bleeding diathesis.
6 Caution should be exercised here: the interpretation of mixing studies is complex. It should be undertaken by either an experienced laboratory coagulation specialist or a haematologist. The degree of the 'correction' in the mixing study may suggest co-existent inhibitor or factor deficiency requiring further investigation.
7 If the APTT does not correct on the initial mixing study, this suggests the presence of an inhibitor. The next step is to perform two dynamic studies: the dilute Russell's viper venom time (DRVVT) and the APTT using Actin FS reagent [24] . If the Actin FS APTT is prolonged but the lupus anticoagulant is not detected, investigations into specific inhibitors against coagulation factors begin, attempting to diagnose conditions such as acquired haemophilia. Bleeding may not stop in patients with an acquired factor inhibitor, so even the smallest insult can be catastrophic.
If an inhibitor is suspected, do not proceed to surgery and discuss with a haematologist.
Abnormal APTT before emergency surgery
A prolonged APTT before emergency surgery necessitates urgent identification of its cause, with the ability to plan haemostatic management quickly.
Mixing studies and an Actin FS APTT should be conducted immediately; this allows for the rapid distinction between a factor deficiency (mixing study) or an inhibitor (Actin FS reagent). If the Actin FS APTT is prolonged the next step would be to undertake pre-operative factor assays to guide haemostatic management, but this takes more time. There should always be a discussion between an anaesthetist, surgeon and haematologist regarding the urgency of surgery, the risk of bleeding and the strategy that is to be employed should bleeding occur.
Conclusion
A thorough pre-operative assessment starts with a detailed bleeding history. It is wise to use, or adapt, one of the many standardised evidence-based bleeding assessment tools [34] . A worthwhile addition to these tools is a full family history [9] .
A coagulation screen should be requested only if indicated and should include the APTT and PT in the first instance, as these tests are able to guide further investigation. If the APTT is outside the reference range, this should be investigated in a stepwise pattern, to exclude accidental heparinisation, the presence of clotting factor defects, lupus anticoagulant or clotting factor inhibitors [23] [24] [25] [26] . A haematologist should manage the investigations which are complex and difficult to interpret. It should also be noted that the patient with a positive bleeding history, but normal APTT, should not be ignored under any circumstances.
Once a definitive diagnosis has been made a multidisciplinary approach should be undertaken to produce a bespoke peri-operative plan to manage bleeding, thromboprophylaxis and follow-up.
